The management of meningiomas, particularly aggressive and recurrent types, remains a significant challenge in neurosurgery. A notable study investigated the efficacy of combining everolimus, an mTOR inhibitor, with octreotide, a somatostatin analog, in patients with recurrent meningiomas who were ineligible for further surgical intervention or radiotherapy. The Phase II CEVOREM trial demonstrated promising results, indicating that this combination therapy could provide an additive antitumor effect, highlighting the need for innovative treatment strategies in this patient population (ref: Graillon doi.org/10.1158/1078-0432.CCR-19-2109/). Furthermore, the identification of epithelial membrane protein 2 (EMP2) as a molecular marker associated with angiogenesis in meningiomas underscores the potential for targeted therapies, as traditional treatment options remain limited (ref: Patel doi.org/10.1007/s11060-020-03401-2/). The literature also emphasizes the benefits of re-do surgeries for recurrent meningiomas, with a comprehensive review of 1469 cases revealing that repeat surgical interventions can lead to favorable outcomes, although the natural history of these recurrences is still not fully understood (ref: Lemée doi.org/10.1038/s41598-019-57254-5/). Additionally, the impact of postoperative radiotherapy on atypical meningiomas has been quantified, showing that factors such as age and extent of resection significantly influence progression-free survival (ref: Keric doi.org/10.1007/s11060-019-03382-x/). Overall, these findings highlight the complexity of meningioma management and the necessity for ongoing research into novel therapeutic approaches.